Animal health company Bayer HealthCare received approval from the United States Food and Drug Administration to market its reproduction management product, ProstaMate. Bayer acquired ProstaMate after the acquisition of Teva Animal Health.

ProstaMate (dinoprost tromethamine) is indicated for use in cattle, pigs and horses. In pigs, its suggested use is for inducing parturition. Federal law restricts the drug to use by or on the order of a licensed veterinarian. 

OvaCyst, a sterile solution that treats cystic ovaries in cattle, was also approved.

"Efficient reproduction is the cornerstone of successful dairy production and cattle herd management," said Dr. Milo Wiltbank, professor of reproductive physiology at the University of Wisconsin. "The proper use of reproductive hormones provides veterinarians and producers effective options that will help reduce labor costs, increase the productivity of their cows and improve the efficiency of their operations." 

Dr. Dirk Ehle, global head of the Bayer HealthCare Animal Health Division, said, "With the launch of these two products we want to support veterinarians and producers who need them. Bayer HealthCare is now active in most major therapeutic areas of the animal health field, with a strong portfolio to support the health of both farm and companion animals."